Обʼєднані Арабські Емірати - англійська - MOHAP (Ministry of Health & Prevention) - وزارة الصحة ووقاية المجتمع.الإمارات

alphamed drug store united arab emirates - 14 capsules - capsule - 40 mg/capsule - gastrointestinal system-ulcer-healing

Ірландія - англійська - HPRA (Health Products Regulatory Authority)

italfarmaco s.a. - calcium carbonate; cholecalciferol - orodispersible tablet - 600/1000 mg/iu - calcium, combinations with vitamin d and/or other drugs

США - англійська - NLM (National Library of Medicine)

boehringer ingelheim animal health usa inc. - cephapirin benzathine (unii: 90g868409o) (cephapirin - unii:89b59h32vn) - cephapirin 300 mg in 10 ml - for the treatment of mastitis in dairy cows during the dry period. tomorrow has been shown by extensive clinical studies to be efficacious in the treatment of mastitis in dry cows, when caused by streptococcus agalactiae and staphylococcus aureus including penicillin-resistant strains. treatment of the dry cow with tomorrow is indicated in any cow known to harbor any of these organisms in the udder at drying off. indicaciones para el tratamiento de mastitis bovina durante el período seco. extensos estudios clínicos han demostrado que tomorrow es eficaz en el tratamiento de la mastitis en vacas secas, cuando ésta es causada por el streptococcus agalactiae y el staphylococcus aureus, incluyendo cepas resistentes a la penicilina. el tratamiento de la vaca seca con tomorrow es recomendado para cualquier vaca que se sepa alberga a cualquiera de estos organismos en la ubre al momento del período de secado. not for human use. este producto no es para administrarse en humanos.

США - англійська - NLM (National Library of Medicine)

elanco us inc. - monensin (unii: 906o0yj6zp) (monensin - unii:906o0yj6zp) - monensin 200 g in 1 kg - instrucciones de uso lea atentamente todas las instrucciones antes de mezclar y ofrecer como alimento principios farmacológicos activos: monensina usp; 90.7 g por libra. - ganado alimentado en condiciones de encierro para faenar: para una mejor eficacia de la alimentación. instrucciones de alimentación: mezclar bien rumensin 90 hasta formar una tonelada de alimento completo que brinde de 5 a 40 g/tonelada de monensina sobre una base de materia seca al 90 % (tabla 1). ofrecer el alimento completo (de 5 a 40 g/tonelada) en forma continua al ganado de res de cría/terminación hasta proporcionar no menos de 50 ni más de 480 mg de monensina por cabeza por día. no se demostró otra mejora en la eficacia de la alimentación por ofrecer monensina en los alimentos en niveles superiores a los 30 g/tonelada (360 mg de monensina por cabeza por día). para la prevención y el control de la coccidiosis a causa de eimeria bovis y de eimeria zuernii . instrucciones de alimentación: alimentar en forma

США - англійська - NLM (National Library of Medicine)

international medication systems, limited - epinephrine (unii: ykh834o4bh) (epinephrine - unii:ykh834o4bh) - epinephrine injection usp, 1 mg/10 ml (0.1 mg/ml) is indicated to increase mean arterial blood pressure in adult patients with hypotension associated with septic shock. none. limited published data on epinephrine use in pregnant women are not sufficient to determine a drug-associated risk for major birth defects or miscarriage. however, there are risks to the mother and fetus associated with epinephrine use during labor or delivery, and risks due to untreated hypotension associated with septic shock (see clinical considerations) . in animal reproduction studies, epinephrine demostrated adverse developmental effects when administed to pregnant rabbits (gastroschisis), mice (teratogenie effects, embryonic lethality, and delayed skeletal ossification), and hamsters (embryonic lethality and delayed skeletal ossification) during organogenesis at doses approximately 15 times, 3 times and 2 times, respectively, the maximum recommended daily intramuscular or subcutaneous dose (see data). the estimated background ris

США - англійська - NLM (National Library of Medicine)

hf acquisition co llc, dba healthfirst - epinephrine (unii: ykh834o4bh) (epinephrine - unii:ykh834o4bh) - 1.1 hypotension associated with septic shock epinephrine injection usp, 1 mg/10 ml (0.1 mg/ml) is indicated to increase mean arterial blood pressure in adult patients with hypotension associated with septic shock. none. 8.1 pregnancy risk summary limited published data on epinephrine use in pregnant women are not sufficient to determine a drug-associated risk for major birth defects or miscarriage. however, there are risks to the mother and fetus associated with epinephrine use during labor or delivery, and risks due to untreated hypotension associated with septic shock (see clinical considerations). in animal reproduction studies, epinephrine demostrated adverse developmental effects when administed to pregnant rabbits (gastroschisis), mice (teratogenie effects, embryonic lethality, and delayed skeletal ossification), and hamsters (embryonic lethality and delayed skeletal ossification) during organogenesis at doses approximately 15 times, 3 times and 2 times, respectively, the maximum recommended daily intramuscular or subcutaneous dose (see data). the estimated background risk of major birth defects and miscarriage for the indicated population is unknown. all pregnancies have a background risk of birth defect, loss, or other adverse outcomes. in the united states general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. clinical considerations hypotension associated with septic shock is a medical emergency in pregnancy which can be fatal if left untreated. delaying treatment in pregnant women with hypotension associated with septic shock may increase the risk of maternal and fetal morbidity and mortality. do not withhold life-sustaining therapy for a pregnant woman. labor or delivery epinephrine usually inhibits spontaneous or oxytocin-induced contractions of the pregnant human uterus and may delay the second stage of labor. avoid epinephrine during the second stage of labor. in dosage sufficient to reduce uterine contractions, the drug may cause a prolonged period of uterine atony with hemorrhage. avoid epinephrine in obstetrics when maternal blood pressure exceeds 130/80 mmhg. although epinephrine may improve maternal hypotension associated with septic shock and anaphylaxis, it may result in uterine vasoconstriction, decreased uterine blood flow, and fetal anoxia. data animal data in an embryofetal development study with pregnant rabbits dosed during the period of organogenesis (on days 3 to 5, 6 to 7, or 7 to 9 of gestation), epinephrine caused teratogenic effects (including gastroschisis) at doses approximately 15 times the maximum recommended intramuscular, subcutaneous, or intravenous dose (on a mg/m2 basis at a maternal subcutaneous dose of 1.2 mg/kg/day for 2 to 3 days).animals treated on days 6 to 7 had decreased number of implantations. in an embryofetal development study, pregnant mice were administered epinephrine (0.1 to 10 mg/kg/day) on gestation days 6 to 15. teratogenic effects, embryonic lethality, and delays in skeletal ossification were observed at approximately 3 times the maximum recommended intramuscular, subcutaneous, or intravenous dose (on a mg/m2 basis at maternal subcutaneous dose of 1 mg/kg/day for 10 days). these effects were not seen in mice at approximately 2 times the maximum recommended daily intramuscular or subcutaneous dose (on a mg/m2 basis at a subcutaneous maternal dose of 0.5 mg/kg/day for 10 days). in an embryofetal development study with pregnant hamsters dosed during the period of organogenesis from gestation days 7 to 10, epinephrine produced reductions in litter size and delayed skeletal ossification at doses approximately 2 times the maximum recommended intramuscular, subcutaneous, or intravenous dose (on a mg/m2 basis at a maternal subcutaneous dose of 0.5 mg/kg/day). 8.2 lactation risk summary there is no information regarding the presence of epinephrine in human milk or the effects of epinephrine on the breastfed infant or on milk production. however, due to its poor oral bioavailability and short half-life, epinephrine exposure is expected to be very low in the breastfed infant. the lack of clinical data during lactation precludes a clear determination of the risk of epinephrine to a breastfed infant. 8.4 pediatric use safety and effectiveness of epinephrine in pediatric patients with septic shock have not been established. 8.5 geriatric use clinical studies of epinephrine for the treatment of hypotension associated with septic shock did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. other reported clinical experience has not identified differences in responses between the elderly and younger patients. in general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.

США - англійська - NLM (National Library of Medicine)

boehringer ingelheim animal health usa inc. - cephapirin benzathine (unii: 90g868409o) (cephapirin - unii:89b59h32vn) - for the treatment of mastitis in dairy cows during the dry period. tomorrow has been shown by extensive clinical studies to be efficacious in the treatment of mastitis in dry cows, when caused by streptococcus agalactiae and staphylococcus aureus including penicillin-resistant strains. treatment of the dry cow with tomorrow is indicated in any cow known to harbor any of these organisms in the udder at drying off. indicaciones para el tratamiento de mastitis bovina durante el período seco. extensos estudios clínicos han demostrado que tomorrow es eficaz en el tratamiento de la mastitis en vacas secas, cuando ésta es causada por el streptococcus agalactiae y el staphylococcus aureus, incluyendo cepas resistentes a la penicilina. el tratamiento de la vaca seca con tomorrow es recomendado para cualquier vaca que se sepa alberga a cualquiera de estos organismos en la ubre al momento del período de secado.

США - англійська - NLM (National Library of Medicine)

remedyrepack inc. - epinephrine (unii: ykh834o4bh) (epinephrine - unii:ykh834o4bh) - epinephrine injection usp, 1 mg/10 ml (0.1 mg/ml) is indicated to increase mean arterial blood pressure in adult patients with hypotension associated with septic shock. none. limited published data on epinephrine use in pregnant women are not sufficient to determine a drug-associated risk for major birth defects or miscarriage. however, there are risks to the mother and fetus associated with epinephrine use during labor or delivery, and risks due to untreated hypotension associated with septic shock (see clinical considerations) . in animal reproduction studies, epinephrine demostrated adverse developmental effects when administed to pregnant rabbits (gastroschisis), mice (teratogenie effects, embryonic lethality, and delayed skeletal ossification), and hamsters (embryonic lethality and delayed skeletal ossification) during organogenesis at doses approximately 15 times, 3 times and 2 times, respectively, the maximum recommended daily intramuscular or subcutaneous dose (see data). the estimated background risk of major birth defects and miscarriage for the indicated population is unknown. all pregnancies have a background risk of birth defect, loss, or other adverse outcomes. in the united states general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. hypotension associated with septic shock is a medical emergency in pregnancy which can be fatal if left untreated. delaying treatment in pregnant women with hypotension associated with septic shock may increase the risk of maternal and fetal morbidity and mortality. do not withhold life-sustaining therapy for a pregnant woman. labor or delivery epinephrine usually inhibits spontaneous or oxytocin-induced contractions of the pregnant human uterus and may delay the second stage of labor. avoid epinephrine during the second stage of labor. in dosage sufficient to reduce uterine contractions, the drug may cause a prolonged period of uterine atony with hemorrhage. avoid epinephrine in obstetrics when maternal blood pressure exceeds 130/80 mmhg. although epinephrine may improve maternal hypotension associated with septic shock and anaphylaxis, it may result in uterine vasoconstriction, decreased uterine blood flow, and fetal anoxia. animal data in an embryofetal development study with pregnant rabbits dosed during the period of organogenesis (on days 3 to 5, 6 to 7, or 7 to 9 of gestation), epinephrine caused teratogenic effects (including gastroschisis) at doses approximately 15 times the maximum recommended intramuscular, subcutaneous, or intravenous dose (on a mg/m 2 basis at a maternal subcutaneous dose of 1.2 mg/kg/day for 2 to 3 days).animals treated on days 6 to 7 had decreased number of implantations. in an embryofetal development study, pregnant mice were administered epinephrine (0.1 to 10 mg/kg/day) on gestation days 6 to 15. teratogenic effects, embryonic lethality, and delays in skeletal ossification were observed at approximately 3 times the maximum recommended intramuscular, subcutaneous, or intravenous dose (on a mg/m 2 basis at maternal subcutaneous dose of 1 mg/kg/day for 10 days). these effects were not seen in mice at approximately 2 times the maximum recommended daily intramuscular or subcutaneous dose (on a mg/m 2 basis at a subcutaneous maternal dose of 0.5 mg/kg/day for 10 days). in an embryofetal development study with pregnant hamsters dosed during the period of organogenesis from gestation days 7 to 10, epinephrine produced reductions in litter size and delayed skeletal ossification at doses approximately 2 times the maximum recommended intramuscular, subcutaneous, or intravenous dose (on a mg/m 2 basis at a maternal subcutaneous dose of 0.5 mg/kg/day). there is no information regarding the presence of epinephrine in human milk or the effects of epinephrine on the breastfed infant or on milk production. however, due to its poor oral bioavailability and short half-life, epinephrine exposure is expected to be very low in the breastfed infant. the lack of clinical data during lactation precludes a clear determination of the risk of epinephrine to a breastfed infant. safety and effectiveness of epinephrine in pediatric patients with septic shock have not been established. clinical studies of epinephrine for the treatment of hypotension associated with septic shock did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. other reported clinical experience has not identified differences in responses between the elderly and younger patients. in general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.

Панама - англійська - Ministerio de Salud (Dirección Nacional de Farmacia Y Drogas)

juste, s.a.q.f. - iohexol (equivalente a iodo) - iohexol (equivalente a iodo)....350.00 mg

Панама - англійська - Ministerio de Salud (Dirección Nacional de Farmacia Y Drogas)

juste, s.a.q.f. - iohexol (equivalente a iodo) - iohexol (equivalente a iodo)....300.00 mg